Glutamate (Glu) and gamma-aminobutyric acid (GABA) are the major neurotransmitters (NTs) in the brain. Being respectively the most common excitatory and the chief inhibitory NTs, Glu and GABA work together through balanced interactions to control many processes, e.g. the overall brain excitation level, and thus maintain homeostasis. However, while prolonged imbalance in glutamatergic and/or GABAergic signaling transmissions is often associated to diseases, such as autism spectrum disorders, neuropsychiatric and mood disorders, and schizophrenia, NT levels can also be affected by external factors and by autoimmunity and genetic disorders. In those diseased conditions, intracellular contents of Glu and GABA as well as their anatomical and functional network are found impaired. Therefore, evaluating anatomo-phenotypic and functional Glu and GABA transmission is critical to address these networks, and thus requires appropriate experimental tools.

To this end, we thus developed and validated antibodies directed against Glu (#IS1001, polyclonal) and GABA (#IS039, monoclonal, and #IS1006, polyclonal). While allowing for the selective immunocytochemical visualization of the putative glutamatergic and GABAergic system networks, our antibodies are perfectly suitable to evaluate these NT-related networks / functions.